I am undergoing a brutal cancelation and moral assassination attempt at my university for defending early treatment. Early treatment is effective and denying it today is causing death and suffering.
Those who design the trials and control the data also control the outcome. So this system of industry-led trials needs to be put to an end.
The death rate from COVID-19 is dramatically low at United Memorial Medical Center in Houston, TX compared to other hospitals across the nation and the world. Despite Dr. Joseph Varon’s popularity on TV, news personalities avoid questions of why he’s having success treating his patients. As it turns out, he’s using drugs the WHO and CDC recommend against.
For months, India’s national authorities have authorized ivermectin as a regimen to be included targeting COVID-19 yet this authorization was then removed due in part to both internal and external political pressure. Now the world’s fourth most populous nation’s regulatory authority has authorised ivermectin’s use in a major breakthrough for the drug’s role in the COVID-19 pandemic.
Oxford University is going to investigate the effectiveness of ivermectin as a COVID-19 treatment. Emeritus Professor Robert Clancy, an immunologist at the University of Newcastle, tells Paul Turton that he believes they’ll find the drug useful, and that it will become part of our coronavirus response.
Pointing out the drug’s safety, this German physician suggested that where ivermectin (Driponin in Germany) is in use, the incidence of COVID-19 goes down.
Large reductions in Covid-19 deaths are possible using ivermectin.
Using ivermectin early may reduce the numbers progressing to severe disease.
Ivermectin is low cost.
The authors concluded based on this extensive review that ivermectin actually reduced the risk of death compared with no ivermectin (average risk ratio 0.38, 95% CI 0.19-0.73; n = 2438; I2 = 49%; moderate-certainty evidence).
“For science to work, you have to have an open exchange of ideas,” Bhattacharya said of the censorship. “If you’re going to make an argument that something is misinformation, you should provide an actual argument. You can’t just take it down and say, ‘Oh, it’s misinformation’ without actually giving a reason.
“We found that when the cumulative doses of two drugs, HCQ and AZM, were above a certain level, patients had a survival rate 2.9 times the other patients,” the authors of the study noted.
Ivermectin is on the WHO’s list of essential medicines and has a high safety profile with more than 3.7 billion doses having been distributed in more than 30 years.
Source: India Today Author: Prabhash K Dutta Hydroxychloroquine, the malaria drug touted as a magical Covid-19 cure by former US President Donald Trump last year,
In a letter dated the 23rd of April, 2021, four Guest Editors publicly resigned from the journal Frontiers in Pharmacology. Professor Maria Cristina Albertini, Professor Piero Sestili, Dr. Robert Malone, and Dr. Howard Haimes stepped down in protest over executive decisions not to publish two papers showing positive results of various agents in protecting against or treating COVID-19.
Over 10,000 patients,a fatality rate more than 97% LOWER than France’s – an exceptional case for early treatment with a drug regimen including HCQ & AZM.
Just as fast as new cases materialized so has the decline thanks in part to a coordinated public health strategy that includes proactive testing, home visits, and medication kits that include ivermectin.
“The significant decline is a tremendous achievement in the fight against COVID-19 and further bolsters our appeal to undertake mass distribution of ivermectin to our people.”
With ivermectin now on the national Indian COVID-19 list of recommended treatments for COVID-19, a few states have gone to the next level and included the low-cost, generic drug approved throughout the world as a parasite fighter as a prophylactic targeting SARS-CoV-2, the virus behind COVID-19.
The kits distributed included ivermectin, aspirin and paracetamol. Between the end of November 2020 and the end of January 2021, more than 200,000 people tested positive for COVID, and of these, nearly 80,000 used the ivermectin kits. Results showed up to 76% reduction in hospitalization in the group that was taking ivermectin.
Zero patients in the ivermectin group that became hospitalized (as compared to 3 in the control group), the results were overall impressive.
Major benefits of ivermectin (IVM) treatment for COVID-19 have been known since the results of 20 such randomized controlled trials (RCTs) were reported
In our carefully considered opinion, the available data on Ivermectin is quite adequate. There is no need to await the outcome of further trials. Any call for local trials prior to approval is unnecessary, as neither time, resources, nor ethical approval would permit.
“Tackling the pandemic probably requires, in addition to a vaccine, a preventive or early-acting drug. This drug also helps especially in a situation where vaccine coverage threatens to remain too low for herd immunity,” said Väänänen.
Leading the national trial is Dr. Carolyn Bramante, a U internal medicine specialist. Emphasizing the importance of this trial, she says, “Not everybody has access to the vaccine, whereas these medications are existing generics, already FDA-approved, that are available in most pharmacies around the world.” Dr. Bramante continued, “If we find evidence of benefit, [the drugs] could be used immediately anywhere.”
Both Goa and Karnataka are rolling out mass Ivermectin programs in a bid to reduce infection, transmission, and death rates associated with COVID-19. TrialSite reported two days ago that the State of Goa embraced the national Ivermectin guidelines, and as reported in The Mint and other outlets, Vishwajit Rane, Goa’s Health Minister, declared that all people 18 years and up would have access to the generic drug regardless of COVID-19 status in an aggressive bid to lower infection rates and total deaths associated with SARS-CoV-2.
At this point, continuing the use of Ivermectin has proven safe and we see no reason to stop this drug, which seems to have not only inhibited our second wave but so far prevented a third one.
“The Minister of Health, Marcelo Queiroga, has announced that he will soon launch a protocol of drugs to be used in the treatment against Covid-19. ”
This guide, which should guide health workers, has, as likely drugs, hydroxychloroquine and ivermectin.
“It [nomination for the Nobel Peace Prize] gives credibility to the message,” Dr. Zelenko said. “Which is, treat Covid-19 early and live.”
n a recent interview, Dr. Stone recently shared that while the death rate climbed much higher in January, again peaking at 70 deaths on the 25th of that month, Official authorization for the use of ivermectin was granted a day later.
A month later, the number of deaths fell to zero. Again, the correlation here along with Dr. Stone’s direct clinic experience is ivermectin sales. Over 500,000 doses of the generic, FDA-approved drug were administered from December through February. This compares to 1,057 bottles turned over in January 2020.
So, what’s different between Maharashtra and Delhi with respect to the rest of India and South Asia? Instead of relying on HCQ and IVM, many doctors and health officials in Maharashtra and Delhi pushed the expensive and profitable remdesivir drug. Due to its cost and recommended time of usage, remdesivir is not used either as a prophylaxis or for early outpatient treatment. And unlike the cheap and easy-to-produce HCQ and IVM, remdesivir is difficult to replace when it runs out.
With a surge of SARS-CoV-2 infections and a vaccination drive totaling 1.3 million, the nation’s leadership faces an uphill battle when factoring in their total population of 108 million. Hence the growing interest in ivermectin and the request of hospitals for access to the drug for compassionate use.
NIH will provide an initial investment of $155 million in funding for the trial. TrialSite picked up inside rumblings that ivermectin will be one of the economical drugs under investigation. While this study is late in the pandemic, nonetheless TrialSite celebrates Collins and team’s movement in this most important of areas. We don’t currently have approved medication to be self-administered by people suffering mild disease at home & reduce the chance of needing hospitalization.
The sales of hydroxychloroquine in the Chinese market have been rising steadily, from CNY 258 million in 2016 to CNY 343 million in 2020, with a CAGR of 7.34% from 2016 to 2020. In 2020, China’s sales of hydroxychloroquine were CNY 343 million, a slight increase of 0.71% than 2019.
MANILA, Philippines — Another private hospital was given a compassionate special permit (CSP) to use Ivermectin as treatment for COVID-19 patients, the Food and Drug Administration (FDA) said yesterday.
Lorigo shared with TrialSite that once doctors learn of all of the studies around the world, and start doing their own homework, they become more open-minded, factoring in the risk-reward analysis. Especially if elderly high risk patients present advanced COVID-19, Lorigo has personally seen the drug potentially contribute to saving the lives of clients. Interestingly, the attorney reports that it would appear that hospital administrations are the most recalcitrant to the idea, even if the patients and the ICU doctor are in support.
The severe weaknesses of this study make it uninformative about whether ivermectin is beneficial in early COVID-19 treatment. Yet, the authors misleadingly conclude that their findings “do not support the use of ivermectin for treatment of mild COVID-19”, as if they had enough quality data to make that case, which they do not.
Ivermectin, a medicine for parasites, has been around for four decades. While not authorized for use against COVID-19, dozens of studies show materially positive results. At well-established human dosage levels, the drug is safe: hundreds of millions of people are treated with it every year mostly in the tropics for various parasite-borne diseases, such as River Blindness in Nigeria.
The authors emphasize the historically significant & relevant role of empiric treatment in an attempt to reduce death. Doing nothing is not good medicine.
The case involving John W. Swanson, a farmer from Stafford in Genesee County, is the latest of several in which judges have ordered local hospitals to give Ivermectin to patients suffering from the virus.
The civil rights organisation AfriForum & Dr George Coetzee today achieved a further success in the fight for access to ivermectin including off-label use.
“I am deeply troubled that the WHO made this hasty decision on guidance before reviewing all available data,” said Pierre Kory, MD, MPH, president and chief medical officer of the FLCCC.
“Their recommendation ignores the evidence, creates more controversy, and will only lead to continuing suffering and death from COVID-19. There are now over 24 randomized trials results
that have been reported to the Unitaid/WHO team yet todays guidance was inexcusably based on a faulty analysis of just 16 of the available trials. Further, these erroneous findings directly conflict
with numerous other peer-reviewed expert analyses that have found the data overwhelmingly demonstrates that ivermectin saves lives from COVID-19. There is no reason not to recommend it
for everyone as a safe drug for prevention and treatment.”
